Sarepta Therapeutics, Inc. (SRPT) earnings date
Feb 24, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 62% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 25 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | after close | 36 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | after close | 36 | 8-K |
| Q4 FY2025 | Wed, Feb 25, 2026 | after close | 56 | 8-K |
| Q3 FY2025 | Mon, Nov 3, 2025 | after close | 34 | 8-K |
| Q2 FY2025 | Wed, Jul 16, 2025 | after close | 16 | 8-K |
| Q4 FY2024 | Wed, Feb 26, 2025 | after close | 57 | 8-K |
| Q3 FY2023 | Mon, Jan 8, 2024 | during market hours | 100 | 8-K |
What they guided beta
| Q3 FY2026 | "Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments – Upcoming multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD expected by year end; Company is actively preparing for Phase 3 development in both programs – Net product revenues for the third quarter 2026 totaled approximately $323.8 million, consisting of approximately $240.3 million of PMO net product revenues and $83.5 million of ELEVIDYS® net product revenue – Continued disciplined financial execution with positive cash flow and GAAP operating loss of ($9.0) million a" exhibit |
| Q3 FY2026 | "DM1 and FSHD programs advancing toward MAD data in fourth quarter of 2026 and preparing for late-stage development: Multiple ascending dose data from SRP-1003 and SRP-1001 are expected in the fourth quarter of 2026, providing important insights including DMPK knockdown and splicing correction in DM1 and DUX4 knockdown in FSHD." exhibit |
| Q3 FY2026 | "The Company expects the PMO franchise to remain strong and is updating its full-year guidance ranges, raising the low end of total net product revenue guidance by $50.0 million to a range of $1.25 billion to $1.3 billion." exhibit |
| Q3 FY2026 | "The Company also narrows its full-year combined non-GAAP R&D and SG&A expenses, lowering the high end of expense guidance by $25.0 million to a range of $800 million to $825 million." exhibit |
| Q2 FY2026 | "ENDEAVOR Cohort 8 expected by year-end 2026 and 12-week data from the full cohort in Q1 2027." exhibit |
| Q2 FY2026 | "Guidance: With six months remaining for the year and consistent with prior expectations toward the lower end of the $1.2-$1.4 billion range, Company narrowed its 2026 total net product revenue guidance to $1.2-$1.3 billion while also narrowing combined non-GAAP R&D and SG&A expense guidance from $800.0-$900.0 million to $800.0-$850.0 million." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/SRPT
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/SRPT
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/SRPT/"><img src="https://veritasdata.dev/embed/SRPT.svg" alt="SRPT earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/SRPT/)
Script
<script async src="https://veritasdata.dev/embed/SRPT.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/SRPT"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.